Who is sponsoring NCT03618082?

NCT03618082 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT03618082?

Interventions in NCT03618082: Anesthesic agent guided by ANI (Interventional Group), Administration of the lowest effective concentration of desflurane (Interventional Group).

What condition does NCT03618082 study?

NCT03618082 studies Immediate Severe Postoperative Pain, Perioperative Hemodynamic.

Is NCT03618082 still recruiting?

NCT03618082 is currently status unknown. Last updated 7 July 2020.

Last reviewed 2020-07-07 · How we verify

NCT03618082: GOALDAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GOAL-Directed ANalgesia (GOALDAN)

Status unknown Phase 3 Last updated 7 July 2020

What this trial tests

Phase 3 trial testing Anesthesic agent guided by ANI (Interventional Group) in Immediate Severe Postoperative Pain in 380 participants. Status unknown.

Timeline

6 June 2019

Primary endpoint
13 May 2022

13 August 2022

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	380
Start date	6 June 2019
Primary completion	13 May 2022
Estimated completion	13 August 2022
Sites	1 location across France

Drugs / interventions tested

Anesthesic agent guided by ANI (Interventional Group) — full drug profile →
Administration of the lowest effective concentration of desflurane (Interventional Group) — full drug profile →

Conditions studied

Immediate Severe Postoperative Pain — all drugs for Immediate Severe Postoperative Pain →
Perioperative Hemodynamic — all drugs for Perioperative Hemodynamic →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

Adults 18 to 65, any sex, with Immediate Severe Postoperative Pain or Perioperative Hemodynamic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of GOALDAN study is to demonstrate the superiority of a targeted perioperative analgesic strategy by the ANI over the usual practice on the incidence of immediate postoperative pain. The investigators hypothesized that a prophylactic administration of morphine in patients with risk of postoperative pain determined by the ANI at the end of the intervention would reduce the incidence of immediate postoperative pain and that the targeted analgesia to ANI and minimal alveolar concentration (MAC) of desflurane could improve the perioperative hemodynamic, and the postoperative becoming.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of GOAL-Directed ANalgesia using ANI (Analgesia/Nociception Index) during general anesthesia on immediate postoperative pain and intraoperative hemodynamics in adult patients (GOALDAN study): a study protocol for randomized, controlled, multicenter trial.
Michalot A, Bazin JÉ, Richebé P, Allaouchiche B, et al · · 2022 · cited 9× · PMID 35468803 · DOI 10.1186/s13063-022-06273-1

Verify or expand the search:

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03618082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 7 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03618082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing